Login to Your Account

Deals And M&A NEWS

HONG KONG – Japan's Chugai Pharmaceutical Co. Ltd. has licensed rights to its treatment for skin diseases to the company's Swiss partner, Galderma Pharma SA.

HONG KONG – Looking to continue morphing from a maker of APIs to a key biologic drug developer and manufacturer, Zhejiang Hisun Pharmaceutical Co. Ltd. has bought the rights to a targeted therapy for epithelioma in China from Nascent Biotech Inc.

Justifying the $1.53 billion price tag for Relypsa Inc., Galenica Group executive chairman Etienne Jornod compared the plan to moves made by his firm in 2008 and 2010.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: